Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma reply

da Silva, IP; Ahmed, T; Reijers, ILM; Warner, AB; Patrinely, JR; Serra-Bellver, P; Allayous, C; Mangana, J; Zimmer, L; Trojaniello, C; Klein, O; Gerard, CL; Michielin, O; Haydon, A; Ascierto, PA; Carlino, MS; Lebbe, C; Lorigan, P; Johnson, DB; Sandhu, S; Lo, SN; Menzies, AM; Long, GV

Long, GV (corresponding author), Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia.; Long, GV (corresponding author), Royal North Shore & Mater Hosp, Dept Med Oncol, Sydney, NSW, Australia.

LANCET ONCOLOGY, 2021; 22 (8): E343

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索